What is Soligenix, Inc.'s market cap?

Soligenix, Inc. (SNGX) has a market capitalization of $5.4M and trades on NASDAQ.

Who are Soligenix, Inc.'s competitors?

Soligenix, Inc.'s key competitors include Emergent BioSolutions, Bausch Health, GT Biopharma Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Soligenix, Inc. partner with?

Soligenix, Inc.'s notable partners include National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority, Defense Threat Reduction Agency, and others.

Where is Soligenix, Inc. headquartered?

Soligenix, Inc. is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 1994.

Soligenix, Inc.

SNGX

Soligenix is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases with significant unmet medical needs.

Market cap

$5.36M+31.5%

Table of contents

Earnings

Q1 2026 report

May 8, 2026

EPS-$0.28Beat by $0.02

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

EPS estimate-$0.16

Competitors

By market cap

BridgeBio Pharma$16.5B+87.7%

Bausch Health Companies$1.7B-34.3%

Regenxbio$621.6M+40.4%

Emergent Biosolutions$378.2M+2.8%

OS Therapies$69.7M+13.9%

HIN

Vyome Holdings, Inc.$14.0M—

GT Biopharma$12.0M+75.3%

Soligenix, Inc.$5.4M+28.4%

By revenue growth

BridgeBio Pharma+355%

Bausch Health Companies+8.2%

Emergent Biosolutions-29.9%

Regenxbio-44.0%

By net margin

Emergent Biosolutions9.62%+36.6pp

Bausch Health Companies-1.88%-9.1pp

BridgeBio Pharma-125.85%+405pp

Regenxbio-330.23%-230pp

Profile

Soligenix is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases with significant unmet medical needs. The company operates through two distinct business segments focused on specialized biotherapeutics for oncology and inflammatory diseases, and public health solutions including vaccines and anti-infectives.

Competitive position

A late-stage clinical developer with a proprietary heat-stabilization platform and a leading candidate in Phase 3 for cutaneous T-cell lymphoma.

GeographiesUnited States, Europe

Customer segmentsGovernment, Healthcare Providers

Business modelR&D intensive, Licensing and Royalties, Government contracting

SuppliersContract manufacturing organizations, Clinical research organizations, Raw material suppliers for synthetic hypericin

CustomersFederal governments, Specialty healthcare providers, Strategic pharmaceutical partners

CountryUnited States of America

Listed1994

Employees15.0

CEOChristopher J. Schaber

SectorHealthcare

IndustryBiotechnology

Websitesoligenix.com

FilingsSEC EDGAR

Questions, answered.

What is Soligenix, Inc.'s market cap?: Soligenix, Inc. (SNGX) has a market capitalization of $5.4M and trades on NASDAQ.
Who are Soligenix, Inc.'s competitors?: Soligenix, Inc.'s key competitors include Emergent BioSolutions, Bausch Health, GT Biopharma Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Soligenix, Inc. partner with?: Soligenix, Inc.'s notable partners include National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority, Defense Threat Reduction Agency, and others.
Where is Soligenix, Inc. headquartered?: Soligenix, Inc. is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 1994.